SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Oncternal Therapeutics, Inc. (ONCT) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+5217.1%).
- Analyst consensus target $28.00 (+5217.1% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 41/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ONCT
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio1.97
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-13.43
Book Value / Share$0.00
Revenue / Share$0.27
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$28.00 (+5217.1%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$-33.72 |
$0.00 |
$-39.41M |
- |
| 2015 |
$-8.86 |
$0.00 |
$-18.7M |
- |
| 2016 |
$-8.52 |
$-2.51M |
$-17.72M |
- |
| 2017 |
$-12.22 |
$1.67M |
$-30.44M |
-1818.3% |
| 2018 |
$-11.52 |
$2.52M |
$-38.42M |
-1523.9% |
| 2019 |
$-30.81 |
$2.43M |
$-15.91M |
-656.2% |
| 2020 |
$-16.95 |
$3.38M |
$-17.21M |
-509.9% |
| 2021 |
$-12.69 |
$4.32M |
$-31.3M |
-725.4% |
| 2022 |
$-16.50 |
$1.49M |
$-43.39M |
-2912.3% |
| 2023 |
$-13.43 |
$785K |
$-39.48M |
-5029.2% |
